These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 15256455

  • 41. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.
    J Clin Oncol; 2007 Nov 20; 25(33):5172-9. PubMed ID: 18024864
    [Abstract] [Full Text] [Related]

  • 42. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.
    Negoro K, Yamano Y, Nakashima D, Saito K, Nakatani K, Shiiba M, Bukawa H, Yokoe H, Uzawa K, Wada T, Tanzawa H, Fujita S.
    Oncol Rep; 2009 Feb 20; 21(2):443-9. PubMed ID: 19148521
    [Abstract] [Full Text] [Related]

  • 43. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response.
    Wang G, Dombkowski A, Chuang L, Xu XX.
    Cell Res; 2004 Aug 20; 14(4):303-14. PubMed ID: 15353127
    [Abstract] [Full Text] [Related]

  • 44. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
    Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E.
    J Clin Invest; 1994 Aug 20; 94(2):703-8. PubMed ID: 8040325
    [Abstract] [Full Text] [Related]

  • 45. The role of glutathione in the regulation of nucleotide excision repair during oxidative stress.
    Langie SA, Knaapen AM, Houben JM, van Kempen FC, de Hoon JP, Gottschalk RW, Godschalk RW, van Schooten FJ.
    Toxicol Lett; 2007 Feb 05; 168(3):302-9. PubMed ID: 17207589
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
    Yoon SO, Shin S, Lipscomb EA.
    Cancer Res; 2006 Mar 01; 66(5):2732-9. PubMed ID: 16510594
    [Abstract] [Full Text] [Related]

  • 49. Transcriptional control of the human high mobility group A1 gene: basal and oncogenic Ras-regulated expression.
    Cleynen I, Huysmans C, Sasazuki T, Shirasawa S, Van de Ven W, Peeters K.
    Cancer Res; 2007 May 15; 67(10):4620-9. PubMed ID: 17510387
    [Abstract] [Full Text] [Related]

  • 50. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB.
    Cancer Chemother Pharmacol; 2007 Feb 15; 59(3):301-12. PubMed ID: 16770583
    [Abstract] [Full Text] [Related]

  • 51. Methylation and inhibition of expression of uPA by the RAS oncogene: divergence of growth control and invasion in breast cancer cells.
    Pakneshan P, Szyf M, Rabbani SA.
    Carcinogenesis; 2005 Mar 15; 26(3):557-64. PubMed ID: 15618232
    [Abstract] [Full Text] [Related]

  • 52. Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6.
    Adachi Y, Shibai Y, Mitsushita J, Shang WH, Hirose K, Kamata T.
    Oncogene; 2008 Aug 21; 27(36):4921-32. PubMed ID: 18454176
    [Abstract] [Full Text] [Related]

  • 53. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells.
    Nishimoto A, Yu Y, Lu Z, Mao X, Ren Z, Watowich SS, Mills GB, Liao WS, Chen X, Bast RC, Luo RZ.
    Cancer Res; 2005 Aug 01; 65(15):6701-10. PubMed ID: 16061651
    [Abstract] [Full Text] [Related]

  • 54. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma.
    Ueda S, Shirabe K, Morita K, Umeda K, Kayashima H, Uchiyama H, Soejima Y, Taketomi A, Maehara Y.
    Ann Surg Oncol; 2011 Apr 01; 18(4):1204-11. PubMed ID: 21076943
    [Abstract] [Full Text] [Related]

  • 58. [Cell signaling and CDDP resistance].
    Masumoto N, Nakano S.
    Gan To Kagaku Ryoho; 1997 Feb 01; 24(4):424-30. PubMed ID: 9063479
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.
    Ko JC, Tsai MS, Kuo YH, Chiu YF, Weng SH, Su YC, Lin YW.
    Biochem Pharmacol; 2011 Mar 01; 81(5):680-90. PubMed ID: 21168393
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.